Evaxion Biotech A/S Files 6-K, Incorporates into Filings

TL;DR

EVX files 6-K, rolls info into existing S-8/F-3/F-1 filings. Standard procedure.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on January 27, 2025, for the month of January 2025. The report is incorporated by reference into several of Evaxion's existing registration statements on Forms S-8 and F-3, as well as multiple F-1 filings. The company is a Danish biotechnology firm specializing in biological products.

Why It Matters

This filing indicates ongoing regulatory compliance and integration of information across various public filings, which is standard for publicly traded companies but essential for maintaining transparency with investors.

Risk Assessment

Risk Level: low — This is a routine filing to incorporate information into existing registration statements, not indicative of new material events.

Key Numbers

• 001-39950 — Commission File Number (Identifies the specific SEC filing record for Evaxion Biotech A/S.)

Key Players & Entities

• Evaxion Biotech A/S (company) — Registrant
• 001-39950 (dollar_amount) — Commission File Number
• 333-255064 (dollar_amount) — Form S-8 File Number
• 333-265132 (dollar_amount) — Form F-3 File Number
• 333-266050 (dollar_amount) — Form F-1 File Number
• 333-276505 (dollar_amount) — Form F-1 File Number
• 333-279153 (dollar_amount) — Form F-1 File Number
• 333-283304 (dollar_amount) — Form F-1 File Number

FAQ

From the Filing

0001171843-25-000423.txt : 20250127 0001171843-25-000423.hdr.sgml : 20250127 20250127082541 ACCESSION NUMBER: 0001171843-25-000423 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250127 FILED AS OF DATE: 20250127 DATE AS OF CHANGE: 20250127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25555822 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 004531262615 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_012725.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), and Form F-1 (File No. 333-283304), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Amendment to Articles of Association On January 24, 2025, the Company sold 696,400 American Depositary Shares (the “ADSs”), representing the Company’s ordinary shares, DKK 0.25 nominal value with each ADS representing fifty (50) ordinary shares, at an average price of USD $7.1776 per ADS. The ADSs were sold in an at-the-market (ATM) offering pursuant to the terms and subject to the conditions contained in that certain Capital Demand™ Sales Agreement between the Company and Jones Trading Institutional Services LLC dated October 3, 2022. After deducting fees and expenses, total proceeds to the Company from the sales of the ADSs were approximately $4.85 million. In connection with such sales, the Company registered a share capital increase of nominal DKK 8,705,000 with the Danish Business Authority, with effect date of January 27, 2025, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 28,365,139 through the issuance of such 696,400 ADSs representing the Company’s ordinary shares. The Company’s Articles of Association were amended as of January 27, 2025, to reflect the capital increase and are attached hereto as Exhibit 1.1. Exhibits Exhibit No. Description 1.1 Articles of Association SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evaxion Biotech A/S Date: January 27, 2025 By: /s/ Christian Kanstrup Christian Kanstrup Chief Executive Officer EX-1.1 2 exh_11.htm EXHIBIT 1.1 Exhibit 1.1 VEDTÆGTER	 /	ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Bi